A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: Clinical and immunological findings

Cancer Immunology, Immunotherapy

Volumn 60, Issue 2, 2011, Pages 261-271

  Oudard, Stéphane ^a,b,c   Rixe, Olivier ^d   Beuselinck, Benoit ^a,b   Linassier, Claude ^e   Banu, Eugeniu ^a,b   MacHiels, Jean Pascal ^f   Baudard, Marion ^g   Ringeisen, François ^h   Velu, Thierry ⁱ   Lefrere Belda, Marie Aude ^a,b   Limacher, Jean Marc ^j   Fridman, W H ^a,b   Azizi, Michel ^a   Acres, Bruce ^j   Tartour, Eric ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d UNIVERSITY OF CINCINNATI   (United States)

^e CHU BRETONNEAU   (France)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g LAPEYRONIE HOSPITAL   (France)

^h HÔPITAL MICHALLON   (France)

ⁱ ERASME HOSPITAL   (Belgium)

^j TRANSGENE S A   (France)

more..

Author keywords

Cytokines; Immune response; MUC1; Renal cell carcinoma; TG4010; Vaccine

Indexed keywords

ALPHA2A INTERFERON; CANCER VACCINE; INTERLEUKIN 2; MUCIN 1; TG 4010; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONNECTIVE TISSUE DISEASE; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; DRUG TOXICITY; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79151471986     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0935-9     Document Type: Article

References (61)

1. J Wesseling SW van der Valk HL Vos, et al. 1995 Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components J Cell Biol 129 255 265 1:CAS:528:DyaK2MXkslKqt7s%3D 10.1083/jcb.129.1.255 7698991
2. M Brayman A Thathiah DD Carson 2004 MUC1: a multifunctional cell surface component of reproductive tissue epithelia Reprod Biol Endocrinol 2 4 10.1186/1477-7827-2-4 14711375
3. J Hilkens F Buijs J Hilgers, et al. 1984 Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors Int J Cancer 34 197 206 1:STN:280: DyaL2c3osl2mtg%3D%3D 10.1002/ijc.2910340210 6206003
4. X Leroy F Zerimech L Zini, et al. 2002 MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma Am J Clin Pathol 118 47 51 1:CAS:528:DC%2BD38Xlslyrsr4%3D 10.1309/1F99-BPDY-7DHH-9G97 12109855
5. S Kraus PD Abel C Nachtmann, et al. 2002 MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: correlation with prognosis Hum Pathol 33 60 67 1:CAS:528:DC%2BD38XhsVGku70%3D 10.1053/hupa.2002.29682 11823974
6. P Brossart KS Heinrich G Stuhler, et al. 1999 Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies Blood 93 4309 4317 1:CAS:528: DyaK1MXjvVGrtLs%3D 10361129
7. JS Goydos E Elder TL Whiteside, et al. 1996 A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma J Surg Res 63 298 304 1:CAS:528:DyaK28XksVOms7k%3D 10.1006/jsre.1996.0264 8667619
8. V Apostolopoulos MS Sandrin IF McKenzie 1999 Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy J Mol Med 77 427 436 1:CAS:528: DyaK1MXkvV2rt7o%3D 10.1007/s001090050373 10426192
9. D Miles K Papazisis 2003 Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer Clin Breast Cancer 3 Suppl 4 S134 S138 10.3816/CBC.2003.s.002 12620150
10. AJ Pantuck A van Ophoven BJ Gitlitz, et al. 2004 Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer J Immunother 27 240 253 1:CAS:528:DC%2BD2cXksVWnsrw%3D 10.1097/00002371-200405000-00009 15076142
11. C Rochlitz R Figlin P Squiban, et al. 2003 Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer J Gene Med 5 690 699 1:CAS:528:DC%2BD3sXnvVShtLo%3D 10.1002/jgm.397 12898638
12. V Karanikas LA Hwang J Pearson, et al. 1997 Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein J Clin Invest 100 2783 2792 1:CAS:528:DyaK2sXotVejsLc%3D 10.1172/JCI119825 9389743
13. R Ramlau E Quoix J Rolski, et al. 2008 A phase II study of Tg4010 (MVA-MUC1-IL2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer J Thorac Oncol 3 735 744 10.1097/JTO.0b013e31817c6b4f 18594319
14. I Keydar CS Chou M Hareuveni, et al. 1989 Production and characterization of monoclonal antibodies identifying breast tumor-associated antigens Proc Natl Acad Sci USA 86 1362 1366 1:CAS:528:DyaL1MXhs12lu70%3D 10.1073/pnas.86.4.1362 2465551
15. A Mayr V Hochstein-Mintzel H Stickl 1975 Abstammung, Eigenschaften und Verwendung des attenuirten Vaccinia-Stammes MVA Infection 3 6 14 10.1007/BF01641272
16. H Stickl V Hochstein-Mintzel A Mayr, et al. 1974 MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) Dtsch Med Wochenschr 99 2386 2392 1:STN:280:DyaE2M%2FjvVGktA%3D%3D 10.1055/s-0028-1108143 4426258 (author's translation)
17. A Mayr H Stickl HK Muller, et al. 1978 The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism Zentralbl Bakteriol B 167 375 390 1:STN:280:DyaE1M7mtFGqtQ%3D%3D 219640 (author's translation)
18. H Meyer G Sutter A Mayr 1991 Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence J Gen Virol 72 Pt 5 1031 1038 1:CAS:528:DyaK3MXksVarur8%3D 10.1099/0022-1317-72-5-1031 2033387
19. G Sutter B Moss 1992 Nonreplicating vaccinia vector efficiently expresses recombinant genes Proc Natl Acad Sci USA 89 10847 10851 1:CAS:528: DyaK3sXjtlOjsA%3D%3D 10.1073/pnas.89.22.10847 1438287
20. JM Tourani C Pfister N Tubiana, et al. 2003 Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design-the Subcutaneous Administration Propeukin Program Cooperative Group J Clin Oncol 21 3987 3994 1:CAS:528:DC%2BD2cXpsVajsbs%3D 10.1200/JCO.2003.02.073 14581421
21. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10.1093/jnci/92.3.205 10655437
22. National Cancer Institute (1999) Common toxicity criteria (CTC), version 2.0. Available at http://ctep.cancer.gov/protocol/development/electronic- applications/docs/ctcv20-4-30-992.pdf
23. A Franzke D Peest M Probst-Kepper, et al. 1999 Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer J Clin Oncol 17 529 533 1:CAS:528:DyaK1MXht1Wmurk%3D 10080596
24. N Bercovici N Haicheur S Massicard, et al. 2008 Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients J Immunother 31 101 112 10.1097/CJI.0b013e318159f5ba 18157017
25. B Godard A Gazagne A Gey, et al. 2004 Optimization of an elispot assay to detect cytomegalovirus-specific CD8 + T lymphocytes Hum Immunol 65 1307 1318 1:CAS:528:DC%2BD2cXhtVSksb%2FE 10.1016/j.humimm.2004.06.006 15556681
26. XF Wang J Kerzerho O Adotevi, et al. 2008 Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients J Immunol 181 431 439 1:CAS:528:DC%2BD1cXnsVGju7Y%3D 18566409
27. LC Heukamp SH van der Burg JW Drijfhout, et al. 2001 Identification of three non-VNTR MUC1-derived HLA-A 0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice Int J Cancer 91 385 392 1:CAS:528:DC%2BD3MXmsFOqsw%3D%3D 10.1002/1097-0215(200002)9999:9999<: :AID-IJC1051>3.0.CO;2-Z 11169964
28. SH van der Burg E Ras JW Drijfhout, et al. 1995 An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A 0301 Hum Immunol 44 189 198 10.1016/0198-8859(95)00105-0 8770631
29. H Van Poppel S Joniau SW Van Gool 2009 Vaccine therapy in patients with renal cell carcinoma Eur Urol 55 1333 1342 10.1016/j.eururo.2009.01.043 19201522
30. S Negrier B Escudier C Lasset, et al. 1998 Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie N Engl J Med 338 1272 1278 1:CAS:528:DyaK1cXivF2qt74%3D 10.1056/NEJM199804303381805 9562581
31. K Fujita K Denda M Yamamoto, et al. 1999 Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients Br J Cancer 80 301 308 1:STN:280:DyaK1Mzhs12jsg%3D%3D 10.1038/sj.bjc.6690355 10390012
32. F Benchetrit A Gazagne O Adotevi, et al. 2003 Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy Bull Cancer 90 1 9
33. C Lonchay P van der Bruggen T Connerotte, et al. 2004 Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen Proc Natl Acad Sci USA 101 Suppl 2 14631 14638 1:CAS:528: DC%2BD2cXovVeqs7o%3D 10.1073/pnas.0405743101 15452345
34. F Pages A Berger M Camus, et al. 2005 Effector memory T cells, early metastasis, and survival in colorectal cancer N Engl J Med 353 2654 2666 1:CAS:528:DC%2BD2MXhtlarsrrE 10.1056/NEJMoa051424 16371631
35. VL Reichardt CY Okada A Liso, et al. 1999 Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study Blood 93 2411 2419 1:CAS:528: DyaK1MXit1Kns7o%3D 10090953
36. DP Scholfield MS Simms MC Bishop 2003 MUC1 mucin in urological malignancy BJU Int 91 560 566 1:CAS:528:DC%2BD3sXjsl2ntLY%3D 10.1046/j.1464-410X.2003. 04132.x 12656915
37. J Wierecky MR Muller S Wirths, et al. 2006 Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients Cancer Res 66 5910 5918 1:CAS:528:DC%2BD28XltFyjurs%3D 10.1158/0008-5472.CAN-05-3905 16740731
38. RJ Amato W Shingler S Naylor, et al. 2008 Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial Clin Cancer Res 14 7504 7510 1:CAS:528:DC%2BD1cXhtlylur3M 10.1158/1078-0432.CCR-08-0668 19010868
39. SA Rosenberg JC Yang DJ Schwartzentruber, et al. 1998 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat Med 4 321 327 1:CAS:528:DyaK1cXhs1Kju7c%3D 10.1038/nm0398-321 9500606
40. JA Sosman C Carrillo WJ Urba, et al. 2008 Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma J Clin Oncol 26 2292 2298 1:CAS:528:DC%2BD1cXntVOltro%3D 10.1200/JCO.2007.13.3165 18467720
41. SZ Josefowicz A Rudensky 2009 Control of regulatory T cell lineage commitment and maintenance Immunity 30 616 625 1:CAS:528:DC%2BD1MXosVCks7o%3D 10.1016/j.immuni.2009.04.009 19464984
42. R Setoguchi S Hori T Takahashi, et al. 2005 Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization J Exp Med 201 723 735 1:CAS:528:DC%2BD2MXitl2rt78%3D 10.1084/jem.20041982 15753206
43. M Ahmadzadeh SA Rosenberg 2006 IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 107 2409 2414 1:CAS:528:DC%2BD28XisFOjtbY%3D 10.1182/blood-2005-06-2399 16304057
44. HJ van der Vliet HB Koon SC Yue, et al. 2007 Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer Clin Cancer Res 13 2100 2108 10.1158/1078-0432.CCR-06-1662 17404092
45. RJ Lechleider PM Arlen KY Tsang, et al. 2008 Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant Clin Cancer Res 14 5284 5291 1:CAS:528:DC%2BD1cXpslKns7g%3D 10.1158/1078-0432.CCR- 07-5162 18698048
46. HL Kaufman B Taback W Sherman, et al. 2009 Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma J Transl Med 7 2 10.1186/1479-5876-7-2 19128501
47. GC Cesana G DeRaffele S Cohen, et al. 2006 Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma J Clin Oncol 24 1169 1177 1:CAS:528:DC%2BD28XislGgsbc%3D 10.1200/JCO.2005.03.6830 16505437
48. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909 915 1:CAS:528:DC%2BD2cXntFSktL0%3D 10.1038/nm1100 15340416
49. CS Higano PF Schellhammer EJ Small, et al. 2009 Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 3670 3679 1:CAS:528:DC%2BD1MXhtVOnurbJ 10.1002/cncr.24429 19536890
50. PW Kantoff TJ Schuetz BA Blumenstein, et al. 2010 Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer J Clin Oncol 28 1099 1105 1:CAS:528:DC%2BC3cXktF2ltLw%3D 10.1200/JCO.2009.25.0597 20100959
51. EA Mittendorf JP Holmes S Ponniah, et al. 2008 The E75 HER2/neu peptide vaccine Cancer Immunol Immunother 57 1511 1521 1:CAS:528:DC%2BD1cXovFyisbY%3D 10.1007/s00262-008-0540-3 18536917
52. RW Griffiths E Elkord DE Gilham, et al. 2007 Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival Cancer Immunol Immunother 56 1743 1753 10.1007/s00262-007-0318-z 17487490
53. JS Ko AH Zea BI Rini, et al. 2009 Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin Cancer Res 15 2148 2157 1:CAS:528:DC%2BD1MXjtF2rurY%3D 10.1158/1078-0432. CCR-08-1332 19276286
54. C Badoual F Sandoval H Pere, et al. 2010 Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies Head Neck 32 946 958 20191626
55. JH Finke B Rini J Ireland, et al. 2008 Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients Clin Cancer Res 14 6674 6682 1:CAS:528:DC%2BD1cXht1KgurzI 10.1158/1078-0432.CCR- 07-5212 18927310
56. J Ozao-Choy G Ma J Kao, et al. 2009 The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies Cancer Res 69 2514 2522 1:CAS:528:DC%2BD1MXjtFyqurY%3D 10.1158/0008-5472.CAN-08-4709 19276342
57. Adotevi O, Pere H, Ravel P et al (2010) A decrease of regulatory CD4+CD25hiFoxp3+ T cells correlate with clinical response after sunitinib based anti-angiogenic therapy regimen in metastatic renal cancer patients J Immunother (in press)
58. H Xin C Zhang A Herrmann, et al. 2009 Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells Cancer Res 69 2506 2513 1:CAS:528:DC%2BD1MXjtFyqurk%3D 10.1158/0008-5472.CAN-08-4323 19244102
59. B Vingert O Adotevi D Patin, et al. 2006 The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity Eur J Immunol 36 1124 1135 1:CAS:528:DC%2BD28Xlt1ektb8%3D 10.1002/eji.200535443 16568496
60. O Adotevi B Vingert L Freyburger, et al. 2007 B Subunit of shiga toxin-based vaccines synergize with {alpha}-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity J Immunol 179 3371 3379 1:CAS:528:DC%2BD2sXpt1SmtLY%3D 17709554
61. C Geiger E Nossner B Frankenberger, et al. 2009 Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma J Mol Med 87 595 612 1:CAS:528:DC%2BD1MXmsFWksbo%3D 10.1007/s00109-009-0455-2 19271159